Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University.
Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties.
Dr. Trivedi’s research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.
|Breast Cancer||[ CLOSED ] A study for women with metastatic breast cancer using study drug LY2835219 for treatment|
|Cancer||[ CLOSED ] Genomic Testing in Cancer|
|Breast Cancer||[ CLOSED ] Study of Combination of Letrozole Plus Letrozole as Endocrine Therapy for Women with Breast Cancer|
|Breast Cancer||[ CLOSED ] Study of Experimental Drug for Triple Receptor-Negative Breast Cancer|
|Breast Cancer||Study to Predict Your Therapeutic Response (I-SPY 2 Trial)|
|Cancer||[ CLOSED ] Assessing Access to and Delivery of Hereditary Breast and Ovarian Cancer Genetic Counseling|
|Cancer||[ CLOSED ] Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (Removal of Fallopian Tube and Ovary)|
|Breast Cancer||[ CLOSED ] Study of Select Immunotherapy Combinations in Patients with Triple Negative Breast Cancer|
|Breast Cancer||[ CLOSED ] Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer|
|Cancer||[ CLOSED ] Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer (lung, breast, ovarian)|
|Breast Cancer||[ CLOSED ] Study of PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer|
|Breast Cancer||Study of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple-Negative Breast Cancer|
|Breast Cancer||Study of Drug - LY3484356 in Patients with Breast Cancer (ER+, HER2-)|
|Breast Cancer||Study of Sacituzumab Govitecan (TRODELVY) in Patients with Triple-Negative Breast Cancer (TNBC)|
|Breast Cancer||Study of Sacituzumab Govitecan in Combination with Pembrolizumab vs. Chemotherapy in Patients with Advanced Triple-Negative Breast Cancer|